| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
BridgeBio Pharma (NASDAQ:BBIO) reported its Q4 earnings results on Thursday, February 22, 2024 at 07:30 AM.
Here's what investors need to know about the announcement.
BridgeBio Pharma missed estimated earnings by 5.49%, reporting an EPS of $-0.96 versus an estimate of $-0.91.
Revenue was down $125 thousand from the same period last year.
Last quarter the company missed on EPS by $0.27 which was followed by a 7.1% increase in the share price the next day.
Here's a look at BridgeBio Pharma's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.81 | -0.83 | -0.83 | -0.85 |
| EPS Actual | -1.08 | -0.98 | -0.92 | -0.92 |
| Revenue Estimate | 4.26M | 2.99M | 3.37M | 4.52M |
| Revenue Actual | 4.09M | 1.64M | 1.83M | 1.87M |
** Listen to the earnings announcement yourself by clicking here. **
To track all earnings releases for BridgeBio Pharma visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: BBIO
